Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is listed today as Janux Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2021 | $125 M | No. 3 | $50 to $250 million | equity | SEC | |
| Mar 2021 | $56 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jun 2020 | $11 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Janux Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).
SEC Form D · Apr 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2021
That is all the official record says: Janux Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Janux Therapeutics, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Avalon BioVentures SPV I, L.P. | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Avalon Ventures XI, L.P. | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Bregua Corp | Company | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| OrbiMed Capital GP VIII LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.
Largest shareholders today
Institutions holding Janux Therapeutics, Inc. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$193 M18.29%
- BlackRock, Inc.$113 M10.68%
- Prosight Management, LP$51 M4.81%
- Federated Hermes, Inc.$45 M4.24%
- FMR LLC$43 M4.10%
- State Street Corp$40 M3.78%
- Vanguard Capital Management LLC$37 M3.52%
- Two Sigma Investments, LP$32 M3.02%
- TCG Crossover Management, LLC$31 M2.92%
- Point72 Asset Management, L.P.$27 M2.58%
- D. E. Shaw & Co., Inc.$26 M2.47%
- Vanguard Portfolio Management LLC$25 M2.37%
- Algert Global LLC$25 M2.32%
- Geode Capital Management, LLC$22 M2.09%
- Alyeska Investment Group, L.P.$19 M1.79%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Campbell, Ph.D. | Executive officer | Apr 2021 |
| Tighe Reardon | Executive officer | Apr 2021 |
| David Campbell, Ph.D. | Director | Apr 2021 |
| Jake Simson, Ph.D. | Director | Apr 2021 |
| Jay Lichter, Ph.D. | Director | Apr 2021 |
| Peter Thompson, M.D. | Director | Apr 2021 |
| Sheila Gujrathi | Director | Apr 2021 |
| Stefan Heller | Director | Apr 2021 |
| Vickie L. Capps | Director | Apr 2021 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.